Raymond James & Associates Sells 2,363 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Raymond James & Associates reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,553 shares of the company’s stock after selling 2,363 shares during the period. Raymond James & Associates owned approximately 0.05% of Vaxcyte worth $3,238,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in PCVX. Vanguard Group Inc. boosted its stake in Vaxcyte by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company’s stock worth $422,331,000 after purchasing an additional 47,872 shares during the period. BlackRock Inc. boosted its position in shares of Vaxcyte by 39.0% in the second quarter. BlackRock Inc. now owns 7,065,088 shares of the company’s stock valued at $352,830,000 after acquiring an additional 1,983,223 shares during the period. Wellington Management Group LLP grew its stake in Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock valued at $234,442,000 after acquiring an additional 167,501 shares in the last quarter. State Street Corp increased its holdings in Vaxcyte by 2.8% during the 2nd quarter. State Street Corp now owns 3,163,312 shares of the company’s stock worth $157,976,000 after acquiring an additional 87,296 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in Vaxcyte by 2,164.2% in the 2nd quarter. Alliancebernstein L.P. now owns 1,888,106 shares of the company’s stock worth $94,292,000 after purchasing an additional 1,804,718 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PCVX. Bank of America boosted their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has an average rating of “Buy” and a consensus target price of $78.50.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $60.73, for a total value of $485,840.00. Following the completion of the sale, the chief financial officer now directly owns 79,474 shares in the company, valued at approximately $4,826,456.02. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Elvia Cowan sold 11,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $74.08, for a total transaction of $865,106.24. Following the transaction, the senior vice president now directly owns 12,480 shares in the company, valued at approximately $924,518.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $60.73, for a total value of $485,840.00. Following the completion of the transaction, the chief financial officer now directly owns 79,474 shares in the company, valued at $4,826,456.02. The disclosure for this sale can be found here. Insiders have sold 109,577 shares of company stock worth $7,426,315 over the last ninety days. Insiders own 3.60% of the company’s stock.

Vaxcyte Stock Down 4.6 %

PCVX opened at $61.88 on Friday. The business’s fifty day simple moving average is $70.65 and its 200 day simple moving average is $60.61. Vaxcyte, Inc. has a 52 week low of $34.56 and a 52 week high of $82.04. The stock has a market cap of $6.71 billion, a PE ratio of -14.98 and a beta of 0.89.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the previous year, the company posted ($0.73) earnings per share. As a group, equities analysts anticipate that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.